Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleAI Now Institute

Multilateralism

View original at ainowinstitute.org
AI Now Institute - Ai Policy Title: Multilateralism Date: 2026-02-12 14:42 Source: https://ainowinstitute.org/publications/multilateralism <div class="wp-block-buttons has-custom-font-size has-medium-font-size is-content-justification-left is-layout-flex wp-container-core-buttons-is-layout-51c3bbf5 wp-block-buttons-is-…
Opening lines of the source · AI Now Institute · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Meta focuses policy agenda on open-weight LLMs while avoiding questions about algorithmic harms on social media platforms like WhatsApp

    80% confidence

  • Corporate partnerships may become unsustainable in the long run as AI model usage scales and costs increase

    80% confidence

  • Meta has influenced how governments regulate AI by pushing for data privacy rules to be weakened against Big Tech

    80% confidence

  • Big Tech companies like Meta, Google, Anthropic, OpenAI, and Hugging Face are always present in policy spaces

    80% confidence

  • Big Tech companies see the Majority World as both a new market to increase revenues and as a source of data to train models

    80% confidence

  • The India AI Impact Summit should shift narrative towards feasible solutions away from grand ideas that may not be implemented

    80% confidence

  • African governments and Global Majority countries need to be intentional about pursuing feasible AI goals rather than lofty objectives

    80% confidence

  • AI Incident databases don't provide much context on issues outside the US, UK, EU, and other Western countries

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com